Transcatheter mitral valve replacement(TMVR)has become an alternative to surgical mitral valve replacement for the treatment of patients with severe mitral insufficiency(MI)who are at very high or prohibitive surgical...Transcatheter mitral valve replacement(TMVR)has become an alternative to surgical mitral valve replacement for the treatment of patients with severe mitral insufficiency(MI)who are at very high or prohibitive surgical risk.[1]Because of impaired left ventricular dysfunction and previous cardiac surgery,some aged patients with degenerated bioprosthetic mitral valve and mitral regurgitation were refused to redo surgery.[2]Increasing demand are required for minimally invasive treatment of these patients.Hundreds of patients worldwide have been treated with a transcatheter mitral valve-in-ring or valve-in-valve procedure using transcatheter aortic valve.[3]However,rare case of transcatheter mitral valve-in-valve/ring replacement using transcatheter mitral valve system was reported.Here,we reported a successfully case of transcatheter mitral“valve-in-valve”replacement for the treatment of bioprosthetic mitral valve degeneration and severe regurgitation with domestic Mithos^TM valve.展开更多
Objectives Transcatheter valve-in-valve （VIV） implantation for failed bioprostheses has become an alternative to open surgery in those deemed high risk. The purpose of this study was to evaluate the effectiveness an...Objectives Transcatheter valve-in-valve （VIV） implantation for failed bioprostheses has become an alternative to open surgery in those deemed high risk. The purpose of this study was to evaluate the effectiveness and outcomes of this emerging procedure. Methods Fourty VIV procedures were performed in 38 consecutive patients （mean age 70 ± 14 years and mean Logistic EuroScore 23.6 ± 15.5%） with severe aortic （n = 19） or mitral （n = 21） bioprosthetic valve dysfunction between 2014 and 2017. Bioprosthetic failure was secondary to stenosis in 11 （27.5%）, regurgitation in 19 （47.5%）, and combined in 10 （25.0%） bioprostheses. Clinical, echocardiographic, and procedural profiles were characterized, and the short-term results of the study patients were reported. Results Successful transfemoral （n = 15）, trans-subclavian （n = 1）, or transapical （n = 3） aortic VIV using either balloon-expandable valves （Edwards Sapien XT, n = 7） or self-expandable valves （Medtronic CoreValve, n = 12）; and transapical （n = 21） mitral VIV using either Edwards Sapien XT （n = 15） or me-chanically expandable valves （Boston Scientific Lotus, n = 6） were accomplished in all 40 VIV procedures. Implantation was successful with immediate restoration of satisfactory valve function in all patients. Five patients （13.2%） died at a median follow up of 9.3 months. Most of the 33 patients alive were in good functional status with good prosthetic valve performance. Conclusions Transcatheter VIV implantation is a feasible and safe option for the management of bioprosthetic valve failure. It may offer a less invasive alternative for those high-risk patients needing repeat valve replacement.展开更多
Transcatheter aortic valve replacement(TAVR)is increasingly used for the treatment of high or very high surgical risk patients with severe aortic stenosis(AS)or failing surgical bioprosthesis(valve-in-valve,VIV-TAVR)....Transcatheter aortic valve replacement(TAVR)is increasingly used for the treatment of high or very high surgical risk patients with severe aortic stenosis(AS)or failing surgical bioprosthesis(valve-in-valve,VIV-TAVR).In TAVR,the collapsed transcatheter heart valve(THV)is introduced using the delivery system inserted from the femoral artery(preferred)or other alternative accesses(transapical,transaortic,transcarotid,subclavian/transinnominate or transcaval).The delivery system is then advanced until coaxially aligned with the aortic annulus,where the THV is deployed.This procedure can be associated with complications such as access site injury(vascular complication),paravalvar leak,cerebrovascular events and conduction disturbances.However,the rapid acceptance and successes observed with TAVR have been made possible through careful patient selection,preprocedural planning(i.e.MDCT annular sizing),THV technology(i.e.new generation valves),and procedural techniques(i.e.minimalist TF-TAVR and alternative percutaneous access options),as well as a decrease in complications as TAVR experience grows.Though the results or ongoing clinical trials evaluating TAVR in intermediate surgical risk patients are pending,it is likely that TAVR will soon be approved for lower risk patients as well.展开更多
BACKGROUND Transcatheter aortic valve replacement(TAVR)is recommended in patients with severe aortic stenosis who have high surgical risk.However,in the pre-existing mechanical mitral valve prosthesis and natural pure...BACKGROUND Transcatheter aortic valve replacement(TAVR)is recommended in patients with severe aortic stenosis who have high surgical risk.However,in the pre-existing mechanical mitral valve prosthesis and natural pure aortic regurgitation,TAVR is relatively contraindicated.In this report,we described one case of TAVR with native aortic regurgitation in the presence of mechanical mitral valve prosthesis.CASE SUMMARY A 64-year-old man with a medical history of mitral valve replacement had severe dyspnea and was symptomatic even at rest for 3 mo.His echocardiography showed severe native pure aortic regurgitation.His euroscore was 15.A TAVR procedure with an evolut R was planned.A 34 mm evolut R was placed by transesophageal echocardiography.The mitral prosthesis was functioning normally,and mild-moderate paravalvular leakage was evident by transesophageal echocardiography.The patient recovered without any complication.At 1 mo follow up,the patient was well,and no paravalvular leakage was noted.CONCLUSION TAVR for pure aortic regurgitation in the presence of prosthetic mitral valve can be a safe procedure.展开更多
Objective To evaluate the efficacy of transcatheter intervention of paravalvular leakage(PVL)after mitral valve replacement.Methods Present respective study included 15 patients(8 males and mean age(53.5±11.7)yea...Objective To evaluate the efficacy of transcatheter intervention of paravalvular leakage(PVL)after mitral valve replacement.Methods Present respective study included 15 patients(8 males and mean age(53.5±11.7)years)with mitral PVL who underwent展开更多
基金supported by the National Natural Science Foundation of China(81600240)the Science Foundation for Distinguished Young Scholars of Shaanxi Natural Science Basic Research Program(2018JC-015).
文摘Transcatheter mitral valve replacement(TMVR)has become an alternative to surgical mitral valve replacement for the treatment of patients with severe mitral insufficiency(MI)who are at very high or prohibitive surgical risk.[1]Because of impaired left ventricular dysfunction and previous cardiac surgery,some aged patients with degenerated bioprosthetic mitral valve and mitral regurgitation were refused to redo surgery.[2]Increasing demand are required for minimally invasive treatment of these patients.Hundreds of patients worldwide have been treated with a transcatheter mitral valve-in-ring or valve-in-valve procedure using transcatheter aortic valve.[3]However,rare case of transcatheter mitral valve-in-valve/ring replacement using transcatheter mitral valve system was reported.Here,we reported a successfully case of transcatheter mitral“valve-in-valve”replacement for the treatment of bioprosthetic mitral valve degeneration and severe regurgitation with domestic Mithos^TM valve.
文摘Objectives Transcatheter valve-in-valve （VIV） implantation for failed bioprostheses has become an alternative to open surgery in those deemed high risk. The purpose of this study was to evaluate the effectiveness and outcomes of this emerging procedure. Methods Fourty VIV procedures were performed in 38 consecutive patients （mean age 70 ± 14 years and mean Logistic EuroScore 23.6 ± 15.5%） with severe aortic （n = 19） or mitral （n = 21） bioprosthetic valve dysfunction between 2014 and 2017. Bioprosthetic failure was secondary to stenosis in 11 （27.5%）, regurgitation in 19 （47.5%）, and combined in 10 （25.0%） bioprostheses. Clinical, echocardiographic, and procedural profiles were characterized, and the short-term results of the study patients were reported. Results Successful transfemoral （n = 15）, trans-subclavian （n = 1）, or transapical （n = 3） aortic VIV using either balloon-expandable valves （Edwards Sapien XT, n = 7） or self-expandable valves （Medtronic CoreValve, n = 12）; and transapical （n = 21） mitral VIV using either Edwards Sapien XT （n = 15） or me-chanically expandable valves （Boston Scientific Lotus, n = 6） were accomplished in all 40 VIV procedures. Implantation was successful with immediate restoration of satisfactory valve function in all patients. Five patients （13.2%） died at a median follow up of 9.3 months. Most of the 33 patients alive were in good functional status with good prosthetic valve performance. Conclusions Transcatheter VIV implantation is a feasible and safe option for the management of bioprosthetic valve failure. It may offer a less invasive alternative for those high-risk patients needing repeat valve replacement.
文摘Transcatheter aortic valve replacement(TAVR)is increasingly used for the treatment of high or very high surgical risk patients with severe aortic stenosis(AS)or failing surgical bioprosthesis(valve-in-valve,VIV-TAVR).In TAVR,the collapsed transcatheter heart valve(THV)is introduced using the delivery system inserted from the femoral artery(preferred)or other alternative accesses(transapical,transaortic,transcarotid,subclavian/transinnominate or transcaval).The delivery system is then advanced until coaxially aligned with the aortic annulus,where the THV is deployed.This procedure can be associated with complications such as access site injury(vascular complication),paravalvar leak,cerebrovascular events and conduction disturbances.However,the rapid acceptance and successes observed with TAVR have been made possible through careful patient selection,preprocedural planning(i.e.MDCT annular sizing),THV technology(i.e.new generation valves),and procedural techniques(i.e.minimalist TF-TAVR and alternative percutaneous access options),as well as a decrease in complications as TAVR experience grows.Though the results or ongoing clinical trials evaluating TAVR in intermediate surgical risk patients are pending,it is likely that TAVR will soon be approved for lower risk patients as well.
文摘BACKGROUND Transcatheter aortic valve replacement(TAVR)is recommended in patients with severe aortic stenosis who have high surgical risk.However,in the pre-existing mechanical mitral valve prosthesis and natural pure aortic regurgitation,TAVR is relatively contraindicated.In this report,we described one case of TAVR with native aortic regurgitation in the presence of mechanical mitral valve prosthesis.CASE SUMMARY A 64-year-old man with a medical history of mitral valve replacement had severe dyspnea and was symptomatic even at rest for 3 mo.His echocardiography showed severe native pure aortic regurgitation.His euroscore was 15.A TAVR procedure with an evolut R was planned.A 34 mm evolut R was placed by transesophageal echocardiography.The mitral prosthesis was functioning normally,and mild-moderate paravalvular leakage was evident by transesophageal echocardiography.The patient recovered without any complication.At 1 mo follow up,the patient was well,and no paravalvular leakage was noted.CONCLUSION TAVR for pure aortic regurgitation in the presence of prosthetic mitral valve can be a safe procedure.
文摘Objective To evaluate the efficacy of transcatheter intervention of paravalvular leakage(PVL)after mitral valve replacement.Methods Present respective study included 15 patients(8 males and mean age(53.5±11.7)years)with mitral PVL who underwent
